Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T71398
(Former ID: TTDS00443)
|
|||||
| Target Name |
Guanylate cyclase (GC)
|
|||||
| Synonyms |
Guanylyl Cyclase
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 5 Target-related Diseases | + | ||||
| 1 | Acquired methaemoglobinaemia [ICD-11: 3A93] | |||||
| 2 | Anal fissure/fistula [ICD-11: DB50] | |||||
| 3 | Angina pectoris [ICD-11: BA40] | |||||
| 4 | Hydrocephalus [ICD-11: 8D64] | |||||
| 5 | Respiratory failure [ICD-11: CB41] | |||||
| BioChemical Class |
Phosphorus-oxygen lyase
|
|||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 4 Approved Drugs | + | ||||
| 1 | Erythrityl Tetranitrate | Drug Info | Approved | Angina pectoris | [3] | |
| 2 | Isosorbide Dinitrate | Drug Info | Approved | Anal fissure | [4], [5] | |
| 3 | Methylene blue | Drug Info | Approved | Acquired methemoglobinemia | [6] | |
| 4 | Nitric Oxide | Drug Info | Approved | Respiratory failure | [7], [8] | |
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | Pirsidomine | Drug Info | Phase 2 | Angina pectoris | [10] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Stimulator | [+] 3 Stimulator drugs | + | ||||
| 1 | Erythrityl Tetranitrate | Drug Info | [1], [11] | |||
| 2 | Isosorbide Dinitrate | Drug Info | [1], [12] | |||
| 3 | Nitric Oxide | Drug Info | [1] | |||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | Methylene blue | Drug Info | [13] | |||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | Pirsidomine | Drug Info | [14] | |||
| Chemical Structure based Activity Landscape of Target | Top |
|---|---|
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. | |||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 3 | Drug information of Erythrityl Tetranitrate, 2008. eduDrugs. | |||||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7051). | |||||
| REF 5 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040009. | |||||
| REF 6 | Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue. FEBS Lett. 1998 Feb 6;422(3):311-4. | |||||
| REF 7 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2509). | |||||
| REF 8 | Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77. | |||||
| REF 9 | ClinicalTrials.gov (NCT03285178) A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) (STRONG SCD). U.S. National Institutes of Health. | |||||
| REF 10 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001151) | |||||
| REF 11 | Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. Metabolism. 1999 Feb;48(2):176-82. | |||||
| REF 12 | No recovery of cold complex regional pain syndrome after transdermal isosorbide dinitrate: a small controlled trial. J Pain Symptom Manage. 2009 Sep;38(3):401-8. | |||||
| REF 13 | Curcumin ameliorates high glucose-induced acute vascular endothelial dysfunction in rat thoracic aorta. Clin Exp Pharmacol Physiol. 2009 Dec;36(12):1177-82. | |||||
| REF 14 | Activation of soluble guanylyl cyclase by the nitrovasodilator 3-morpholinosydnonimine involves formation of S-nitrosoglutathione. Mol Pharmacol. 1998 Jul;54(1):207-12. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.